Deeming Duravyu’s path forward in diabetic macular edema “very viable” after Monday's data drop, analyst Graig Suvannavejh, Ph.D., said Mizuho Securities considers EyePoint's drug-device combo a ...
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of ...
Hopes remain for Unity Biotechnology Inc.’s UBX-1325 in diabetic macular edema (DME) following a phase II miss in wet age-related macular degeneration (AMD), where data from part A of the study called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results